Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 4/2019

01-08-2019 | Arterial Diseases | Original Article

Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers

Authors: Haifa Abdulla Al-Muhtaresh, Abdel Halim Salem, Ghada Al-Kafaji

Published in: Journal of Cardiovascular Translational Research | Issue 4/2019

Login to get access

Abstract

Circulating miRNAs are increasingly suggested as clinical biomarker for diseases. We evaluated the expression of circulating cardiomyocyte-enriched miR-1 and miR-133 by real-time PCR in blood from patients with type 2 diabetes (T2D) without and with coronary artery disease (CAD) and healthy controls, investigated their association with the risk of CAD risk and their potential as biomarkers. The two miRNAs were upregulated in patients with T2D and CAD compared with controls, associated with CAD risk and remained significant after adjustment for multiple confounders. LDL-C was a positive predictor for miR-1 and miR-133, and mean blood pressure was also a positive predictor for miR-133. Both miRNAs strongly distinguished CAD from controls. miR-1 significantly distinguished CAD from T2D with higher diagnostic ability than miR-133, whereas the miR-1/miR-133 combination improved the diagnostic value. Upregulation of circulating miR-1 and miR-133 associate with the risk of CAD in T2D patients and may serve as diagnostic biomarkers.
Literature
1.
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047–1053.CrossRefPubMed
2.
3.
Alhyas, L., McKay, A., & Majeed, A. (2012). Prevalence of type 2 diabetes in the states of the co-operation council for the Arab states of the Gulf: A systematic review. PLoS One, 7, e40948.PubMedPubMedCentralCrossRef
4.
Nathan, D. M. (1993). Long-term complications of diabetes mellitus. The New England Journal of Medicine, 328, 1676–1685.PubMedCrossRef
5.
Laakso, M. (2010). Cardiovascular disease in type 2 diabetes from population to man to mechanisms: The Kelly West Award Lecture 2008. Diabetes Care, 33, 442–449.PubMedPubMedCentralCrossRef
6.
Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992). The pathogenesis of coronary artery disease and the acute coronary syndromes. The New England Journal of Medicine, 326, 242–250.PubMedCrossRef
7.
Libby, P., & Theroux, P. (2005). Pathophysiology of coronary artery disease. Circulation, 111, 3481–3488.CrossRefPubMed
8.
Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., et al. (2007). Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ, 334(7588), 299.PubMedPubMedCentralCrossRef
9.
Li, G., Zhang, P., Wang, J., Gregg, E. W., Yang, W., Gong, Q., et al. (2008). The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet, 371, 1783–1789.PubMedCrossRef
10.
Bartel, D. P. (2004). Micrornas: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 181–197.CrossRef
11.
He, L., & Hannon, G. J. (2004). Micrornas: Small rnas with a big role in gene regulation. Nature Reviews. Genetics, 5, 522–531.PubMedCrossRef
12.
Kloosterman, W. P., & Plasterk, R. H. (2006). The diverse functions of microRNAs in animal development and disease. Developmental Cell, 11, 441–450.PubMedCrossRef
13.
Latronico, M. V., Catalucci, D., & Condorelli, G. (2007). Emerging role of microRNAs in cardiovascular biology. Circulation Research, 101, 1225–1236.PubMedCrossRef
14.
Pandey, A. K., Agarwal, P., Kaur, K., & Datta, M. (2009). MicroRNAs in diabetes: Tiny players in big disease. Cellular Physiology and Biochemistry, 23, 221–232.PubMedCrossRef
15.
Ardekani, A. M., & Naeini, M. (2010). The role of microRNAs in human diseases. Avicenna Journal of Medical Biotechnology, 2, 161–179.PubMedPubMedCentral
16.
Condorelli, G., Latronico, M. V., & Cavarretta, E. (2014). microRNAs in cardiovascular diseases current: Knowledge and the road ahead. Journal of the American College of Cardiology, 63(21), 2177–2187.PubMedCrossRef
17.
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105, 10513–10518.PubMedPubMedCentralCrossRef
18.
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research, 18, 997–1006.PubMedCrossRef
19.
Meder, B., Keller, A., Vogel, B., Haas, J., Sedaghat-Hameddani, F., Kayvanpour, E., et al. (2011). MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Research in Cardiology, 106, 13–23.PubMedCrossRef
20.
Al-Kafaji, G., Al-Mahroos, G., Alsayed, N. A., Hasan, Z. A., Nawaz, S., & Bakhiet, M. (2015). Peripheral blood microRNA-15a as a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Molecular Medicine Reports, 12(5), 7485–7490.PubMedCrossRef
21.
Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H. A., Skrypnyk, C., Sabry, M. A., & Ramadan, A. R. (2016). Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Experimental and Therapeutic Medicine, 12(2), 815–822.PubMedPubMedCentralCrossRef
22.
Al-Kafaji, G., Al Naieb, Z. T., & Bakhiet, M. (2016). Increased oncogenic microRNA-18a expression in peripheral blood of patients with prostate cancer: A potential role as new noninvasive biomarker. Oncology Letters, 11(2), 1201–1120.PubMedCrossRef
23.
Al-Muhtaresh, H., & Al-Kafaji, G. (2018). Evaluation of two-diabetes related microRNAs suitability as earlier blood biomarkers for detecting prediabetes and type 2 diabetes mellitus. Journal of Clinical Medical, 7(2), 12.CrossRef
24.
Fichtlscherer, S., De Rosa, S., Fox, H., Schwietz, T., Fischer, A., Liebetrau, C., et al. (2010). Circulating microRNAs in patients with coronary artery disease. Circulation Research, 107, 677–684.PubMedCrossRef
25.
Rao, P. K., Kumar, R. M., Farkhondeh, M., Baskerville, S., & Lodish, H. F. (2006). Myogenic factors that regulate expression of muscle-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 103, 8721–8726.PubMedPubMedCentralCrossRef
26.
Townley-Tilson, W. H., Callis, T. E., & Wang, D. (2010). MicroRNAs 1, 133, and 206: Critical factors of skeletal and cardiac muscle development, function, and disease. The International Journal of Biochemistry & Cell Biology, 42, 1252–1255.CrossRef
27.
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016). Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). Journal of Molecular and Cellular Cardiology, 94, 107–121.PubMedCrossRef
28.
Zhao, Y., Samal, E., & Srivastava, D. (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature, 436, 214–220.PubMedCrossRef
29.
Ikeda, S., He, A., Kong, S. W., Lu, J., Bejar, R., Bodyak, N., et al. (2009). MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Molecular and Cellular Biology, 29, 2193–2204.PubMedPubMedCentralCrossRef
30.
Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., et al. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nature Genetics, 38, 228–233.PubMedCrossRef
31.
Wang, G., Zhu, J., Zhang, J., Li, Q., Li, Y., He, J., et al. (2010). Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. European Heart Journal, 31, 659–666.PubMedCrossRef
32.
Kuwabara, Y., Ono, K., Horie, T., Nishi, H., Nagoa, K., Kinoshita, M., et al. (2011). Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circulation. Cardiovascular Genetics, 4(4), 446–454.PubMedCrossRef
33.
Briasoulis, A., Tousoulis, D., Vogiatzi, G., Siasos, G., Papageorgiou, N., Oikonomou, E., et al. (2013). MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus. Current Topics in Medicinal Chemistry, 13(13), 1533–1539.PubMedCrossRef
34.
Al-Kafaji, G., Al-Mahroos, G., Al-Muhtaresh, H., Sabry, M. A., Abdul Razzak, R., & Salem, A. H. (2017). Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. Biomarkers, 22(3–4), 268–278.PubMedCrossRef
35.
AL-Subaihi, A. (2003). Sample size determination. Influencing factors and calculation strategies for survey research. Saudi Medical Journal, 24(4), 323–330.PubMed
36.
Alberti, K. G., & Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine, 15, 539–553.PubMedCrossRef
37.
38.
Feng, Y., Niu, L.-L., Wei, W., Zhang, W.-Y., Li, X.-Y., Cao, J.-H., & Zhao, S.-H. (2013). A feedback circuit between miR-133 and the ERK1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation. Cell Death & Disease, 4, e934.CrossRef
39.
Wong, L., Lee, K., Russell, I., & Chen, C. (2007). Endogenous controls for real time quantitation of miRNA using TaqManVR MicroRNA assays. New York: Macmillan Publishers Ltd..
40.
Roggli, E., Britan, A., Gattesco, S., Lin-Marq, N., Abderrahmani, A., Meda, P., et al. (2010). Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes, 59, 978–986.PubMedPubMedCentralCrossRef
41.
Poy, M. N., Hausser, J., Trajkovski, M., Braunc, M., Collinsc, S., Rorsmanc, P., et al. (2009). miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proceedings of the National Academy of Sciences of the United States of America, 106, 5813–5818.PubMedPubMedCentralCrossRef
42.
Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., et al. (2007). MicroRNA-133 controls cardiac hypertrophy. Nature Medicine, 13, 613–618.PubMedCrossRef
43.
Terentyev, D., Belevych, A. E., Terentyeva, R., Martin, M. M., Malana, G. E., Kuhn, D. E., et al. (2009). miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circulation Research, 104, 514–521.PubMedPubMedCentralCrossRef
44.
Luo, X., Lin, H., Pan, Z., Xiao, J., Zhang, Y., Lu, Y., et al. (2008). Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. The Journal of Biological Chemistry, 283, 20045–20052.PubMedCrossRef
45.
Williams, A. H., Liu, N., van Rooij, E., & Olson, E. N. (2009). MicroRNA control of muscle development and disease. Current Opinion in Cell Biology, 21, 461–469.PubMedPubMedCentralCrossRef
46.
Liu, N., Bezprozvannaya, S., Williams, A. H., Qi, X., Richardson, J. A., Bassel-Duby, R., et al. (2008). microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes & Development, 22, 3242–3254.CrossRef
47.
D’Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P. G., et al. (2010). Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. European Heart Journal, 31, 2765–2773.PubMedPubMedCentralCrossRef
48.
Matheus, A. S., Tannus, L. R., Cobas, R. A., Palm, A. C. C., Negrato, C. A., & Gomes, M. B. (2013). Impact of diabetes on cardiovascular disease: An update. International Journal of Hypertension, 2013, 653789.PubMedPubMedCentralCrossRef
49.
Dokken, B. B. (2008). The pathophysiology of cardiovascular disease and diabetes: Beyond blood pressure and lipids. Diabetes Spectrum: A Publication of the American Diabetes Association, 21(3), 160–165.CrossRef
50.
Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., Jr., & Fuster, V. (1999). Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American heart association and the American college of cardiology. Circulation, 100, 1481–1492.PubMedCrossRef
51.
Howard, B. V., Robbins, D. C., Sievers, M. L., et al. (2000). LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong heart study. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 830–835.PubMedCrossRef
52.
Escobar, E. (2002). Hypertension and coronary heart disease. Journal of Human Hypertension, 16(1), S61–S63.PubMedCrossRef
53.
Otsuka, T., Takada, H., Nishiyama, Y., Kodani, E., Saiki, Y., Kato, K., & Kawada, T. (2016). Dyslipidemia and the risk of developing hypertension in a working-age male population. Journal of the American Heart Association, 5, e003053.PubMedPubMedCentralCrossRef
54.
de Gonzalo-Calvo, D., van der Meer, R. W., Rijzewijk, L. J., Smit, J. W. A., Revuelta-Lopez, E., Nasarre, L., et al. (2017). Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Scientific Reports, 7(1), 47.PubMedPubMedCentralCrossRef
55.
Zhang, Z., Joyce, B. T., Kresovich, J. K., Zheng, Y., Zhong, J., Patel, R., et al. (2017). Blood pressure and expression of microRNAs in whole blood. PLoS One, 12(3), e0173550.PubMedPubMedCentralCrossRef
56.
Jepsen, A. M., Langsted, A., Varbo, A., Bang, L. E., Kamstrup, P. R., & Nordestgaard, B. G. (2016). Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clinical Chemistry, 62(4), 593–604.PubMedCrossRef
57.
Sampson, U. K., Fazio, S., & Linton, M. F. (2012). Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges. Current Atherosclerosis Reports, 14(1), 1–10.PubMedPubMedCentralCrossRef
58.
Fruchart, J. C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., Cuevas, A., Farnier, M., et al. (2014). Residual macrovascular risk in 2013: What have we learned? Cardiovascular Diabetology, 13(1), 26.PubMedPubMedCentralCrossRef
59.
Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., & Bush, T. L. (2001). Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Archives of Internal Medicine, 161, 1413–1419.PubMedCrossRef
60.
Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003). Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. The strong heart study. Diabetes Care, 26(1), 16–23.PubMedCrossRef
61.
Kroh, E. M., Parkin, R. K., Mitchell, P. S., & Tewari, M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods, 50, 298–301.PubMedPubMedCentralCrossRef
62.
Metadata
Title
Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers
Authors
Haifa Abdulla Al-Muhtaresh
Abdel Halim Salem
Ghada Al-Kafaji
Publication date
01-08-2019
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 4/2019
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-018-9857-2

Other articles of this Issue 4/2019

Journal of Cardiovascular Translational Research 4/2019 Go to the issue

Original Article

Profound Increase of Lung Airway Resistance in Heart Failure: a Potential Important Contributor for Dyspnea

Original Article

Ex Vivo Pilot Study of Cardiac Magnetic Resonance Velocity Mapping for Quantification of Aortic Regurgitation in a Porcine Model in the Presence of a Transcatheter Heart Valve

Original Article

Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model

Correction

Correction to: Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data

Original Article

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

Original Article

A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of Concept

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits